GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Cash, Cash Equivalents, Marketable Securities

Nutriband (Nutriband) Cash, Cash Equivalents, Marketable Securities : $0.49 Mil (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nutriband Cash, Cash Equivalents, Marketable Securities?

Nutriband's quarterly cash, cash equivalents, marketable securities declined from Jul. 2023 ($2.34 Mil) to Oct. 2023 ($1.27 Mil) but then stayed the same from Oct. 2023 ($1.27 Mil) to Jan. 2024 ($0.49 Mil).

Nutriband's annual cash, cash equivalents, marketable securities declined from Jan. 2022 ($4.89 Mil) to Jan. 2023 ($1.99 Mil) and declined from Jan. 2023 ($1.99 Mil) to Jan. 2024 ($0.49 Mil).


Nutriband Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Nutriband's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Cash, Cash Equivalents, Marketable Securities Chart

Nutriband Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 0.01 0.15 4.89 1.99 0.49

Nutriband Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.99 1.28 2.34 1.27 0.49

Nutriband Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Nutriband  (NAS:NTRB) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Nutriband Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Nutriband's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutriband (Nutriband) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801
Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Executives
Michael Davidov director 60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan director, 10 percent owner, officer: CEO 6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros director, 10 percent owner, officer: Chairman of the BOD GREGERSTR 36B, FISHAMEND C4 2401